Item 8.01. Other Information.

On January 9, 2020, Prevail Therapeutics Inc. issued a press release announcing that it has granted a compassionate use request for the administration of PR001 to a single patient with Type 2 Gaucher disease, and separately that the Company is proceeding with its Phase 1/2 clinical trial for the treatment of neuronopathic Gaucher disease and expects to initiate patient dosing during the first half of 2020.

A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



               Exhibit
                 No.     Description

               99.1        Press Release dated January 9, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses